Pharmaceutical Analysis & Statistics, October 2014

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Publishers

  • All
    • Global Data

All regions

You might be interested in: therapeutics, drug, cancer, more »

1-30 of about 6 000 reports

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 Summary The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the ...

  • Industries : Pathology
  • Countries : United States
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018 Summary The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the ...

  • Industries : Therapy
  • Countries : United States, World
PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, World, Europe
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : Spain, France, Italy, Germany, United Kingdom, Europe, World
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : China
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Japan
PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

  • Industries : Drug and Medication
  • Countries : Australia
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : United States
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

  • Industries : Drug and Medication
  • Countries : Japan
EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 Summary Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascula ...

  • Industries : Pathology
  • Countries : Germany, Japan, China, World, United States
EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 Summary Allergic conjunctivitis is an inflammation of the eye resulting from an allergic reaction to allergy causing substances (external ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany
EpiCast Report: Asthma - Epidemiology Forecast to 2023

EpiCast Report: Asthma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Asthma - Epidemiology Forecast to 2023 Summary Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term ...

  • Industries : Pathology
EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • September 2014
  • by Global Data

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that ...

  • Industries : Pathology
  • Countries : Japan, World
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • August 2014
  • by Global Data

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part ...

  • Industries : Pathology
  • Countries : Japan, China, World, United States, Spain, Italy, France, Germany
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Dulera (Asthma) - Forecast and Market Analysis to 2023

Dulera (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dulera (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dulera (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : World, United States
Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flutiform (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
About 57 000 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Accessed 29 Oct 2014 01:39 Gmt Gmt
  • October 2014
    7 pages
  • Cancer  

  • United States  

View report >

95 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

Covidien PLC

Ireland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.